Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution

U.S. Food and Drug Administration published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy by means of greater safety compared to Xy... Biopharmaceuticals, FDA Jazz Pharmaceuticals, Xywav, Cataplexy, Narcolepsy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Epilepsy Behav. 2021 Sep 14;124:108311. doi: 10.1016/j.yebeh.2021.108311. Online ahead of print.ABSTRACTExcessive daytime sleepiness (EDS) and attentional deficits are often observed in people with epilepsy. They may be the consequence of seizures and subclinical discharges as well as of comorbid conditions as obstructive sleep apnea/hypopnea syndrome (OSAS), attention deficit hyperactivity disorder (ADHD), or other less frequent disorders. Excessive daytime sleepiness may also be caused or worsened by antiseizure medications (ASMs). Several meta-analyses suggested that lamotrigine, lacosamide, and perhaps eslicarbazepine ...
Source: Epilepsy and Behaviour - Category: Neurology Authors: Source Type: research
On the one hand, amphetamine (racemic D,L-amphetamine, ratio 1:1) is used as an illegal drug; but on the other hand, especially D-amphetamine serves to treat narcolepsy and preferentially activity deficiency/ hyperactivity disorder (ADHD). Recently, in Ger...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Curr Neuropharmacol. 2021 Sep 9. doi: 10.2174/1570159X19666210909144930. Online ahead of print.ABSTRACTIn contrast to that of other monoamine neurotransmitters, the association of the histaminergic system with neuropsychiatric disorders is not well documented. In the last two decades, several clinical studies involved in the development of drugs targeting the histaminergic system have been reported. These include the H3R-antagonist/inverse agonist, pitolisant, used for the treatment of excessive sleepiness in narcolepsy, and the H1R antagonist, doxepin, used to alleviate symptoms of insomnia. The current review summarizes ...
Source: Current Neuropharmacology - Category: Drugs & Pharmacology Authors: Source Type: research
ConclusionAlthough rarely manifested through symptoms suggestive of diencephalic involvement, NMOSD should be considered when encountering patients with the diencephalic syndrome to identify the primary cause of these manifestations.
Source: Acta Neurologica Belgica - Category: Neurology Source Type: research
Eur J Paediatr Neurol. 2021 Aug 31;34:118-122. doi: 10.1016/j.ejpn.2021.07.011. Online ahead of print.ABSTRACTThis review article covers the vaccination related issues in autoimmune disorders of central nervous system (CNS) including narcolepsy, anti-NMDAR encephalitis, Rasmussen encephalitis and febrile infection related epilepsy syndrome (FIRES). Beyond these conditions the immune mediated epilepsies related with autoimmune CNS disorders are discussed and indications and contraindications of vaccinations in these cases are also considered.PMID:34487956 | DOI:10.1016/j.ejpn.2021.07.011
Source: European Journal of Paediatric Neurology - Category: Neurology Authors: Source Type: research
In this study, we report on the cases of a kindred carrying theDNMT1 variant NM_001130823.2:c.1531 T  >  C (p.Y511H) presenting with the ADCA-DN phenotype. The review of the literature further revealed that later ages at onset and the presence of cerebellar ataxia are the main characteristics of patients carrying the DNMT1 p.Y511H as compared with those carrying DNMT1 p.Y511C. Although HSAN1E and AD CA-DN are proposed to be called DNMT1-complex disorders owing to their overlapping symptoms, this finding suggests a distinct genotype–phenotype correlation regarding the DNMT1 p.Y511H and p.Y511C variants.
Source: Journal of Molecular Neuroscience - Category: Neuroscience Source Type: research
ConclusionsMinimally important difference and clinically important response estimates for the FOSQ-10 for adults with excessive daytime sleepiness in narcolepsy or obstructive sleep apnea will be helpful for interpreting changes over time and defining a clinical responder.ClinicalTrials.gov identifiersNCT02348593 (first submitted January 15, 2015) and NCT02348606 (first submitted January 15, 2015)
Source: Sleep and Breathing - Category: Respiratory Medicine Source Type: research
Journal of Clinical Sleep Medicine, Ahead of Print.
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Authors: Source Type: research
Journal of Clinical Sleep Medicine, Ahead of Print.
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Authors: Source Type: research
.
Source: Expert Opinion on Therapeutic Targets - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Calcium | Food and Drug Administration (FDA) | Magnesium | Narcolepsy | Pharmaceuticals | Potassium | Sleep Medicine | Sodium